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Ekctrophysiologic testing has been useful in guiding therapy 
in patients with wrtained ventricular tachycardia treated 
with conventional antiarrhythmic drug3 (1.2). This is based 
on the premise that drugs that suppress the induction of 
ventricular tachvcardia in the $oxa!or:’ are elctive. 
for at lea five half-lives (that is. when scmm drug concen- 
trations are at steady state). 
The role af programmed electrical stimulation in the 
management of patients treated with amiodarone remains 
contr~vcrs~al G-16). Most vadents with inducible ventricu- 
lar arrhythmia who are studied with programmed electrical 
stimulation within a few weeks of starting amiodarone ther- 
apy continue to have inducible anhythmia. However, many 
of these pants continue to do well despite their inducible 
state. In addition, previous studies (17.18) have shown that 
the clectraphyriologic effects of amiodarone after a single 
intravenous dose differ from those observed after high dose 
oral loading. This suggests that the electrophysiologic effects 
of amiodarone may change over time. However. the changes 
in electrophysiologic etTects between oral loading and steady delivering impulses of 2 rns duration at twice diastolic 
state are less well characterized W-15). threshold. Data were displayed on an oscilloscope (Elec- 
The purposes ofthis study were I) to explain the disparity trenicsfer Medicine VR-12) and recorded atepaperspeed of 
between amiodarone atd cmnentional drug response to 50 no 100 mmls. Conduction intervals were measured in 
programmed electrical stimulation: 2) to compare the lec- standard fashion. The maximal sinus node recovery time 
trophysiologic effects of oral amiodarone after oral loading was calculated as previously described (19). Sinoatrial con- 
and at stead” stale: and 31 10 determine whether the re- duction time was calculated by the method of Strauss et al. 
sponse to p&ommed electrical stimulation is helpful in 
oredictina clinical outcome. 
(20). Incremental atrial pacingwas performed until atriovcn- 
triadar (AV) block developed. Atrial refractory periods 
were detemdned at a oaced cvcle lenath of 60 ms 
Methods 
Pr&mmwd ven&dar sknufamurari~ was then petformed 
usine sinale. double and triole extrastimuli at three ven- 
study patients. This prospective study consisted of 42 tricu~ar paced cycle lengths &JO, 500 and 4W ms). Stimula- 
patients with L history of one or mere episodes of sympto- lion was repeated at the right ventricular oWlow tract if 
matic ventricular techycardia or ventricular fibrillation. In sustained ventricular tachycxdia war not induced et the 
each case, the alrhythmic episode was not associated with right ventricular apex. The end point ofthe protocol was the 
myocardial ischemia or infarction, metabolic disturbance or induction of sustained monomorphic ventricular tachycar- 
proarrhythmic drug effect. All patients had ventricular dia. If nonsustained ventricular tachycardia or polymorphic 
tachycardia induced by programmed electrical stimulation in ventricular tachycardia was induced. the stimulation pmto- 
the drug-free state. The patients ranged in age from 41 to 14 col was continued until sustained ventriculc tachycardia or 
“ears lmean see 62): there were 34 me” and 8 women. ventricular fibrillation was initiated or completion of the 
&iy-iour patients had coronary artery disease, ven had Protocol. 
caniiomvooathv and one had valvular heart disease. Of Amiodarwendminisbrdiion. After the contml electrophy_ 
those p&nts with coronary artery disease. 33 (97%) of 34 siologic study, patients began the amiodarone loading &i- 
had a history of transmuml ywardial infarction; in each, it men. The loading dose of amiodarune consisted of I,200 
had occurred at least 6 weeks before initial evaluation. The me/day for a mean of 12 ? 2 days. Forty patients received 
mean ejection fraction for the entire gmup was 30 + 13%. the loading dose orally in divided doses, and two patients 
Before initiation of amiodamne theraov. 20 oatients had received half the dose intravenouslv and half omllv. After 
documented sustained ventricular tachy&dii, &td IO had a the loading dose, leetrophysiolo~ctesting was m&ted as 
cardiac arrest during which ventricular tachycardia or fibril- during the initial ekctropbysiologic study, and is designated 
lation was recorded. Four patients had presyncopc during a as early clectrophysiol&ic testing. At this time, st&dard 
spantanenus episode of nonsustained ventricular tachycar- ekctrophysiologic variables were measured and anempts to 
dia, and eight additional patients experienced syncope after reinduce ventricular tachycardia were made using pm- 
an episode that strongly suggested the presence of a tach- grammed stimulation. The ventricular stimulation protocol 
yarrhythmia. All 20 patients with sustained ventricular was the same as in the control study (that is, up to three 
tachycardia had a monomorphic arrhythmia documented by extrastimuli at three ventricularpaced cycle lengths from the 
either I2 lead electrocardiogram (ECG) or ambulatory mon- right ventricular apex and outflow tract, regardless of the 
itoring. All patients had had at least one unsuccersfol drug initial mode of induction). The induction of ventricular 
trial bchre starting nmicdamne. fibrillation was considered an end point only if it ws induced 
Electrophysir&gic study protocol. Patients were brought at the initial study. The stimulation protocol was eootimted 
to the electrophysiology laboratory in the postabsorptive until monomorphic tachycardia was induced or the protocol 
nonsedated state after all antiarrhythmic digs had been was completed. Induced polymorphic ventricular tachycw 
discontinued for at least five half-lives. All patients who dias were not considered as an end point of inelttded in the 
received digoxin, beta-receptor blockers or calcium channel analysis of arrhythmia inducibility during amiodarone [her. 
blockers at the time of the cantml study continued to receive WY. 
them at the time of all subsequent studies. Two quadripolar Patients were rhen discharged from the hospiro/ on n 
pacing catheters were inserted percutaneously into a femoral mainrenance dose $400 mglday of amiodnrone. Three 
win and advanced to the high right Prium and right ventric- patients received concomitant oral procainamide because 
ular apex. A trip&r catheter was inserted into the opposite rapid ventricular tachycardia was induced at early elec- 
femoral vein and advanced across the tricuspid valve for trophysiologic testing. All other patients were treated with 
recording of the His potential. Surface ECG leads I, aVF and oral amiodarone alone. After a minimum of 3 months of 
V, were recorded along with intracardiac electrograms fil- therapy, consenting patients returned at a mean of 17 + 4 
tered at 30 to 500 Hz. Cardiac stimuMion was performed weeks for late electmphysiologic testing. Nineteen patients 
using a programmed digital stimulator (Bloom Associates), did not return for late electro~hystologic testing: four pa 
ticnts did not have inducible arrhythmias et early etecrmphy 
siologic testing. four had a recwrenee before 3 months. IWO 
died a “onsudden death (“nc from acute myocardial inferc- 
tion and one from congestive heart failure! and nine refused 
further study. Electrophysiologic variables were measured 
agtin, and programmed stimulation was repeated. Patientr 
were then followed up clinically whde r&tog “ml amio- 
darone (400 mg daily), regardless of the results of late 1 
eleclrophysiologic testing and were see” every 2 I” 3 months 
in the arrhythmia clinic. 
Definitiotts. %stained ventricular tachycardia was de- 
fined as a tachycardia ias:ing 30 s or rcquirmg termmation a 
before 30 s because of hemoxiynamic ompromise. Non- 
f 
sustained ventrtcular tachycardia was defined as a tachycar- 
dia lasting far SIX complexes to 30 s in duration. in this 
study, ooly induced monomorphic tachycardias were used 
as an end point for therapy. After amiodarone therapy. a . 
tachycardia was considered inducible f >I5 beats of yen- 
tricular tachycardia were induced by any pOrtion of the Figon 1. Changes in ventricular tachycardia i*aducibility behveen 
prot”coI, regardless of the initial mode or site of stimulation. coetml study and early electmphysiologic testing in 42 patients. Nt 
During amicdarone therapy, the techycardia was considered = nonmduable: NSVT = nonsustained “entricelarlachyc~dirdia: YF 
nonsustained if it lasted >I5 complexes but ~30 s. and 
= “entnc”lar6brill*tion;YT-S = swleined venlrifulartachy~ardia. 
sustained if it lasted >30 s or required termination. The 
techycardia was considered noninducible if ~15 complexes significantly pmlonged atrial and veotricular efractoriness 
of ventricular tachycardia were initiated by the complete while slowing AV node cod His-Porkioje c”nd”cti”” tp = 
stimulation protocol at both the right ventricular apex and O.uOIL Paced cycle length to AV Wenckebach block was the 
outflow tnc*. only varieblc that significantly changed from early to late 
The clinical responsr m rhe induced venrricalar tochycar- electrophyslologic testing (501 + 86 to 547 * 89 ms, p < 
diu WE considered tolerated if the induced arrhythmia did 0.05). 
not cause cardiovascular collapse, angina. near wocop~ or El&t of amiedamne on indecibiiitv of *mtrieutar tib- 
systolic arterial pressure 480 mm Hgl rardis. All 42 patients had inducible ~enlriculartachyeerd~e 
Statistical amalysis. The data ere presented as mea” I or fibrillation at the control study. In 35 patients. the induced 
standard deviation. Electmphysiologic data were tested for ventricular tachycardia was sustained, and in 4 patients. it 
sigcificance by paired t tests (Systat). Clinical response was was nonsustained; two of the latter four Patients had a 
tested using chi-square analysis. A p value <0.05 was history of prior cardiac arrest. Ventricular fibrillation was 
considered significant. induced in the remaining three patients. 
Amiianwe levels. Serum concentmtions of amiodaronc The resrrlrs of pro~ramnwd rrimuiurion ofrer crs! ado- 
and derethylamiodarooe were determined at early and late 
electrophysiologic testing in the first II patients using pre- 
viously described methods (21). 
&wow boding bk s%mmarized in Figure 1: Among the 35 
patients with inducible sustained wntricular tachycardia t 
control study, the arrhythmia remained inducible at early 
electmphysiologic testing  30. became nonsustained in two 
RtSOltS 
and and became noninducible in 3. Ofthe three patients with 
ventricular fibrillation, one had inducible sustained ventricu- 
Electmphysiulogic elf&s cd amtednmne. In the 42 pa- ler tachycardia, one bed no change, and in one the arrbyth- 
tients assessed at early elcctrophysiologic testing, amicda- mia became noninducible. Ofthe four patients with inducible 
rone pmlooged the paced cycle length to AV Wenckebach nonsustained ventricular tachycardia, the arrhythmia be- 
block from 406 ? 82 to 493 + 88 ms and the AH interval from came sustained in three and remained nonsustained in one. 
85 ? 24 to 107 L 31 ms. In addition, the HV interval Therefore. of 42 patients studied with programmed slim”16 
increased from 52 2 II to 59 * I3 ms. The atrial effective [ion after amiodamne loading, a total of 4 (10.5%~ had “o 
refractory period increased from 256 r 36 to 292 ? 44 ms, inducible arrhythmia. 
the ventricular effective refractory period increased from 258 Twenty-three of the patients with inducible ventricular 
+ 30 to 295 2 27 ms and the corrected QT interval increased tachycardia returned for late electmphysiologic testing (Fig. 
from 418 * 37 to 461 ? 49 ms. Therefore. on the basis of 2). Of 22 patients who had inducible sustained ventricular 
results from early electmpbysiology testing, amiodarone tachycardia t early study, the arrhythmia remained induc- 
ible in 15, was inducible but nonsustained in 2 and became 
noninducible in 5. The remaining patient with nonsustained 
ventricular tachycardia induced at early study who was 
restudied developed noninducible ventricular tachycwdia. 
Therefore, at late electraphysiologic testing, an additional 6 
(26%) of 23 patients had noninducible v ntricular tachycar- 
dia. 
tesdng. ventricular tachycardia was inducible in 3 patients 
with single. 21 patients with double and 14 patients with 
triple extrastimuli. At late electmphysiologic testing, ven- 
tricular tachycardia was inducible in one patient with single, 
nine patients with double and seven patients with triple 
extrastimuli. Only 5 of the 24 patients whose tachycardia 
was induced with single or double extrastimuli atthe control 
study required a third extrastimulus for induction at subse- 
quent studies. 
Cycle length of induced ventricular tachycardia. The 
mean cycle length of induced ventricular tachycardia in- 
creased from 275 C 61 ms at control study to 340 ? 58 ms at 
early electmphysinlogic testing (p = 0.W). Ventricular 
tachycardiacyde length continued to increase from 341 r 38 
ms at early electrophyriologic testing to 37) ? 63 ms at late 
electrophysiologic testing in the 17 patients who still had 
inducible arrhythmias at the late study (p < 0.05). 
Clinical fotlow.~p. The relation of outcome to the results 
of early and late programmed stimulation was evaluated 
(Fig. 3). Of the 42 patients tudied with early electmphysic- 
logic testing 4 had no inducible arrhythmias (I with ventric- 
ular fibrillation and 3 with sustained ventricular lachycardia 
induced at control study); all 4 have had no recurrences. 
Among the 23 patients who underwent late electmphysiolo- 
gic testing and were followed up for a mean of 21.7 months 
(range 4 to 47), there were no recurrences among the 6 
patients with noninducible arrhythmias, but there were five 
recurrences among the I7 patients with persistently induc- 
ible arrhythmias. Of these live patients with recurrences. 
four died suddenly and one had tolerated sustained ventric- 
ular tachysardia. 
Fifreen of the 38 parienrs who had inducible vennicular 
Mgure 3. Relation of outcome to results ot 
eariv and Iale programmed snmulation i  42 
patients. 
for iire study. Of tkse I5 &enh.b had rc&enr veotnc- 
ular tachycardia bcforc 3 months (I had sudden death and 3 
bad tolerated sustained ventricular tachycardia). The II 
remaining patients have been followed up for a mean of 16.3 
months. There have been four recweoces; two patients died 
suddenly and two had toter ucd sustamzd ventncular thchy- 
cardia. Therefore, recurrent ventncolar tachycardla or sud- 
den death hasoccurred in I3 (3l%)of42 in the original study 
group treated with or?1 amiodarone. No clinical or ekc- 
trophy#iologic variable other than inducibility states was 
useful in predicting which patients would have clinical 
recurrences. The mean ejectloo fraction was 27 2 I I% for 
the patients with naninducible arrhyrhmias and 32 ? 14% for 
the patients with pzrsistcntly inducible arrhythmias (o = 
NS). 
CIInicnl response to the induced ventricular tarhyeardia. 
This was evaluated in the 23 oatients who had both earlv and 
late electrophysiologic k&g (Fig. 4). At control s&y, 5 
(22%) of 23 patients bad tolerated tachycardia induced. and 
at early study 8 (34%) of 23 patients had tolerated tachycar- 
dia (p = KS). At late study, 6 (26%) of 23 patients had 
noninducible arrhythmias, and 9 (53%) of 17 patients with 
inducible tachycardia had inducible tolerated tachycardia. 
Therefore, as patients were treated longer with amiodarone, 
more tachycardias became either tolerated or noninducible 
(p c O.OI). Of note are two patients who hxd nontolerated 
tachycardia induced at early electrophysiolugic testing. Both 
patients were treated with concomitant oral procainamide 
after it was demonstrated that the addition of introvenous 
proainamide produced further slowing and improved toler- 
awe of the induced tachvcardia. Both oatients were studied 
at late electrophy~iolagi~~testing while receiving amiodarone 
only and bad tolerated tachycardia induced. During fol- 
low-up study, two of nine patients with tolerated tachycardia 
had recurrences; one had tolerated sostained ventricular 
txhycardia and one died soddenly I month after lowering 
Fgure 4. Clinical response to the induced venrdeutnr tachycardia 
atcach study in the 23 patients with both early and late ekctrrphys- 
iologic testing. The pweot of patients with tolerated or nocinduc- 
Me tachycardia increass over tune. 
he dox of amiodarone on his own. Three of the eight 
pahents with nontolerated tachycardia at late ekctrophy& 
logic testmg had recurrences; all three patients died sud- 
denly. As prcvrourly stated. there were no recurrences in the 
six patients with noninducible tachycardta. 
Amiodarune ~erurn c~,ncentratio~. These were analyzed 
in the hcst It parienrs that had borh early and late elec- 
trophydolugic testing. At early ekctrophysiolodc testing. 
serum amiodarone &centration was 2.11 + 0.91 verses 
2 38 2 1.16 dml at late study (p = NS). The level of 
deselhylamiodarone was 1.02 + 0.65 dml at early study 
and 1.36 ? 0.55 jlglm, at \ate study (p = NSI. 
The major findings of this study ore that: I) The timing of 
programmed electrical stimulation will affect the resnks of 
the study in patients trated with oral amiodarone. At steady 
slale as compared wth early electrophyriotogic resting, the 
oerceot of oatienw who do not have inducible anhvtbmias is 
higher andmore patients have better tolerated tachycardias. 
2) P&cots who do not have ;nducibk arrhythmias while 
receiving amiodarone appear to be at low risk for recorrcor 
arrhythmias and sudden death. 3) Serial programmed ekc- 
hical stmwlation may be useful in stratifyin patients wit:! 
I!fe-thre&xdng ventricular arrhythmias treated with oral 
amiodamne. 
Changes in wNric&r tachycardb indttcibitity and cyck 
kngtb. Several srudies C-16) have examined the response 
to oroorammed stimulation after amiodarone theraw. The 
m&i~y of patients wre free of clinical recumnce~despite 
continued inducibility. This has led some to suggest that 
programmed stimulation is of little value and that empiric 
therapy is indicated (4-V. In previous studies, arrhythmia 
became nonioducibk in 5 to 53% of patients after adminis- 
tration of amiodarone. In comparing the results of prc+ 
graroroed c:ectrical stimulation, it is imponant to note di- 
ferences in the groups of patienrs studied. as well as the 
timine of the follow-ua electroohv~ioloeic stttdv. Such di- 
feren~es may helpex&in the div.& &Its of progmmmed 
stimulation. 
In previous wudies. there was gnat variability and incon- 
sistencv in the timioeoforomzmmcd x!imutation. which was 
pwfoied by somei&&Wxs (4.11) as arty as 2 days 
zfter starting amiodarone. while others (5.7.9.16) waited 3 to 
4 weeks. Our data suggest that the timing of the study will 
inftuence the results. Our palients were synemalically stud- 
Ied after oral loading doses (12 z 2 days) and after 4 months 
of therapy (mean 17 f 4 weeks). Althoush arrhythmia war 
noninducible in only 10.5% of patients after the initial 
loading dose, it became oooinducibk in an additional 26% at 
late electropbysiologic testing. In addition, induced tachy- 
cardia cycle length was prolonged from 215 + 61 ms at 
conttul to 340 +_ 58 ms at early study (p = 0.001). At late 
study, there was evidence of further prolongation of tachy- 
cardia cycle lenath from 341 + 38 to 375 f 63 ms (P < 0.05). 
Th& chat&s in inlcibility and tachycordio cycle 
lenad demonware a rumporal dependence of the elec- 
rroihysiologic egecrs of amiodomne. The cause of this time 
dependence is unknown. Proposed mechanisms include a 
change m the ratio of desethylamiodarone to amiodarone. 
Although we did not demonstrate such a change. !wo previ- 
ous studies (13,17) have shorn an increase in the desethy- 
lamiodaronelamiodarone rotio with time. TalJic et al. (23) 
demonstrated that desethylamiodarone produces greater so- 
dium channel blockade than does its parent compound. This 
may account for the further prolongation of tachyardia 
cycle length observed at late electrophysiologic testing. 
Other mechanisms that might account for the temporal 
changes seen include intracellular effects of amiodamne, 
which mighttaketime to develop, or the secondaryeffectsof 
amiodorone on thyroid metabolism as uggested by Momdy 
HV in&w% In addition, serum concentrations of amioda- 
ronc and desethylamiadarooe were unchanged from early to 
late study. These oteasoros of refractoriness and conduction 
reflect changes in noninfarcted myocardial tissue. The deter- 
minants of conduction and refractoriness within the disdared 
reentrant circuit may be quite different from those localized 
to the right ventricular apex. The absence of correlation 
between these measured variables and the results of late 
electrophysiologic testing suggest hat this may be possible. 
Clinical follw-up. In our patients, there were no recur- 
rences of ventricular tachycardia in the IO noninducible 
patients with arrhythmia. while 5 of 17 with arrhythmia that 
was still inducible at late ekctropbysiologic testing had 
recurrences. In addition, the clinical ootcoote was similar to 
the clinical response to the induced tachycardia. Three of 
eight patients with nontolerated tachycardia at late elec- 
trophysiologic testing died suddenly, whereas only one of 
nine who had a tolerated tachycardia died suddenly. This 
tatient had decreased his dose of amiodarooe and oresoot- 
ably oo longer had adequate worn levels of amiodarone. 
Another finding is that some patients have tolerated tachy- 
cardis at late electmphysiologic testing even if the arrhyth- 
mta is poorly tolerated initi&lly. It seems appropriate to 
provide an alternative or additive (that is, a combined) drug 
regimen for these potieots until amiodarone reaches its 
steady state effect. 
Comparison with previous studies. Several other studies 
have evaluated patients early and late in the course of 
amiodamne therapy. Kadish et al. (13) evaluated 29 patients 
with recurrent swained ventricular tachycardia or cardiac 
wrest with early (2 weeks) and late (after mean of 5 months) 
electrophysiologic testing. Twenty-one of22 patients tudied 
early had inducible anhythmia, while 26 of 29 hod inducible 
arrhythmia t late study. The predictive value of their early 
and late study is difficult to assess because many of their 
patients were takine: a concomitant vpe I antiarrhythmic 
brag. None of oar p&nts received ai aotiarrhythmic drug 
in addition to amiodamne after late electrophysiologic test- 
ing. Wyndham et al. (24) observed that the percent of 
patients whose arrhythmia becomes noninducible during 
amiodarone therapy increases over lime. Fe&k et al. (25) 
also observed that the percent of patients with noninducible 
arrhythmia changed after 2 weeks and 3 months of therapy. 
The optimal timing of late electrophy+ologic testing was not 
addressed by these studies. 
Clinical implicotionr. Patients with life-threatening veo- 
tricolar arrhythmia treated with amiodarone may he risk 
stratified with serial electmphysiologic testing. Those with- 
out inducible arrhythmia appear to be at low risk for recur- 
rent arrhvthmia. whereas those with continued induction of 
ventricular tachycordia re at high risk. Although we could 
not find any clinical or electrophysiologic variable that 
predicted recurrence. those patients with inducible poorly 
tolerated tachycwdias were at relstive risk for sudden death. 
Whereas the percent of Patients niih no indacible arthyth- 
mia while receiving amiodarone o?pears to change over 
time, it is not clinically feasible to wait several months 
before electrophysiologic testing. Therefore, electrophysio- 
logic testing has generally been petfomted after oral loading. 
Ii a poorly tolerated tachycardia is induced at early elec- 
trophysiologic testing, the addition of a type I aotiarrhythmic 
agent may sufficiently slow the tachycardia rate to produce 
hemodynamic benefit. If rapid tachycardia is still inducible 
at either early or late study, an alternative therapy such as 
implantationbf an interttoj defibrillator or a&thmia sw- 
gay should be explored. In patients with an automatic 
implantable defibrillator that uses the rate of ventricular 
tachycardia for detection, late electmphysialogic testing is 
indicated because ventriculot tachycardia cycle l ngth pro- 
longs between the loading dose period and steady state. 
Amiodarone is an extremely effective drug for the treat- 
ment of life-threatening arrhythmias. However, in our study 
group, I3 (31%) of 42 patieo& sti:l had recurrent arrhythmia, 
and 7 of the 13 died suddenly. S&i electmphysiologic 
studies may be useful in developing treatment strategies in 
patients with life-threatening ventricular arrhythmias treated 
with amiodarone. 

